AASraw
AASraw aims to be the most trusted CDMO of API !
- Oct 22, 2017
- 285
- 39
The first FDA approved GLP-1 drug is exenatide (Byetta), in 2005. From 2005 to 2024, GLP-1 drugs have been used for the treatment of type 2 diabetes for over a decade. Over the years, several other GLP-1 agonists have been developed and approved for type 2 diabetes and obesity, here below are some of the most popular GLP-1 agonists list in 2024. Some GLP-1 agonists have the same generic name but are marketed under a different brand name and are approved for a different purpose, depending on the dose and how they are taken.
①Semaglutide
Semaglutide is a GLP-1 agonist that has been used for a longer period of time. Semaglutide was previously only used for type 2 diabetes, but now it can also be used for obesity and long-term weight management, and there is now an oral Semaglutide. Semaglutide mimics the GLP-1 hormone, which stimulates insulin production to lower blood sugar, thus effective treat type 2 diabetes. GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness. When combined with diet and exercise, semaglutide leads to significant weight reduction, with many users losing 15-20% of their body weight.
②Tirzepatide
Not only GLP-1 drug, Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.Tirzepatide is a synthetic peptide, Patent own by original Manufacturer Eli Lilly, and marketed under the brand names Mounjaro and Zepbound. Tirzepatide is a novel medication designed for the treatment of type 2 diabetes and obesity or overweight with at least one weight-related comorbid condition. Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion. This dual action helps improve glycemic control by promoting insulin production when needed and reducing excess glucose production by the liver. Additionally, Tirzepatide slows gastric emptying, which can reduce postprandial blood sugar spikes and promote a feeling of fullness, aiding in weight management. Tirzepatide is rather new GLP-c agonist than Semaglutide, but may lead to greater weight loss compared to semaglutide.
③Mazdutide
Mazdutide is not only a GLP-1 agonist but also Glucagon Receptor agonist. By activating both the GLP-1 receptor and the glucagon receptor, Mazdutide has the ability to regulate appetite, metabolism, and significantly improve glycemic control in a variety of ways. Mazdutide is still under phase 3 trials but Mazdutide for research already on sale in some online peptide manufacturer.
④Retatrutide
Same manufacturer as Mounjaro, Retatrutide is an experimental medication for treating type 2 diabetes and obesity. Now is in phase 3 of clinical trials. Whereas Semaglutide has a single mechanism of action as a GLP-1 agonist, retatrutide has three mechanisms, it calls GLP-1/GIP/glucagon tri-agonist. That means retatrutide may be even more effective than Semaglutide and Tirzepatide. Retatrutide works by mimicking the effects of natural hormones that help control blood sugar levels and reduce body weight. By activating the GLP-1 and GIP receptors, Retatrutide enhances insulin secretion and inhibits glucagon release, leading to improved glycemic control. Additionally, its action on the glucagon receptor promotes energy expenditure and reduces appetite, contributing to significant weight loss.
⑤CagriSema
CagriSema is a combination medication by GLP-1 agonist Semaglutide and an amylin analog Cagrilintide. It is a long-term Effective combination therapy for the treatment of type 2 diabetes and obesity. Due to it contains semaglutide and cagrilintide two ingredients, it works by mimicing the action of GLP-1 hormones and amylin. GLP-1 increases insulin secretion, reduces glucagon release, and slows gastric emptying, helping to control blood sugar levels. helping to control blood sugar levels. Amylin helps regulate blood sugar levels by slowing gastric emptying and promoting satiety. The dual mechanism makes CagriSema achieve more weight reduction compare to either medication alone.
①Semaglutide
Semaglutide is a GLP-1 agonist that has been used for a longer period of time. Semaglutide was previously only used for type 2 diabetes, but now it can also be used for obesity and long-term weight management, and there is now an oral Semaglutide. Semaglutide mimics the GLP-1 hormone, which stimulates insulin production to lower blood sugar, thus effective treat type 2 diabetes. GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness. When combined with diet and exercise, semaglutide leads to significant weight reduction, with many users losing 15-20% of their body weight.
②Tirzepatide
Not only GLP-1 drug, Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.Tirzepatide is a synthetic peptide, Patent own by original Manufacturer Eli Lilly, and marketed under the brand names Mounjaro and Zepbound. Tirzepatide is a novel medication designed for the treatment of type 2 diabetes and obesity or overweight with at least one weight-related comorbid condition. Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion. This dual action helps improve glycemic control by promoting insulin production when needed and reducing excess glucose production by the liver. Additionally, Tirzepatide slows gastric emptying, which can reduce postprandial blood sugar spikes and promote a feeling of fullness, aiding in weight management. Tirzepatide is rather new GLP-c agonist than Semaglutide, but may lead to greater weight loss compared to semaglutide.
③Mazdutide
Mazdutide is not only a GLP-1 agonist but also Glucagon Receptor agonist. By activating both the GLP-1 receptor and the glucagon receptor, Mazdutide has the ability to regulate appetite, metabolism, and significantly improve glycemic control in a variety of ways. Mazdutide is still under phase 3 trials but Mazdutide for research already on sale in some online peptide manufacturer.
④Retatrutide
Same manufacturer as Mounjaro, Retatrutide is an experimental medication for treating type 2 diabetes and obesity. Now is in phase 3 of clinical trials. Whereas Semaglutide has a single mechanism of action as a GLP-1 agonist, retatrutide has three mechanisms, it calls GLP-1/GIP/glucagon tri-agonist. That means retatrutide may be even more effective than Semaglutide and Tirzepatide. Retatrutide works by mimicking the effects of natural hormones that help control blood sugar levels and reduce body weight. By activating the GLP-1 and GIP receptors, Retatrutide enhances insulin secretion and inhibits glucagon release, leading to improved glycemic control. Additionally, its action on the glucagon receptor promotes energy expenditure and reduces appetite, contributing to significant weight loss.
⑤CagriSema
CagriSema is a combination medication by GLP-1 agonist Semaglutide and an amylin analog Cagrilintide. It is a long-term Effective combination therapy for the treatment of type 2 diabetes and obesity. Due to it contains semaglutide and cagrilintide two ingredients, it works by mimicing the action of GLP-1 hormones and amylin. GLP-1 increases insulin secretion, reduces glucagon release, and slows gastric emptying, helping to control blood sugar levels. helping to control blood sugar levels. Amylin helps regulate blood sugar levels by slowing gastric emptying and promoting satiety. The dual mechanism makes CagriSema achieve more weight reduction compare to either medication alone.
